Use of 5-methylcytidine in the preparation of a medicament for treating polycystic ovary syndrome

By using 5-methylcytidine to modify ovarian RNA in polycystic ovary syndrome (PCOS) drugs, the problem of existing treatments being unable to simultaneously improve key pathological phenotypes of PCOS was solved, achieving synergistic improvement in ovarian function and metabolic disorders.

CN122140743APending Publication Date: 2026-06-05NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NANTONG UNIV
Filing Date
2026-03-11
Publication Date
2026-06-05

Smart Images

  • Figure CN122140743A_ABST
    Figure CN122140743A_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine, and specifically discloses application of 5-methylcytidine in preparation of a medicine for treating polycystic ovary syndrome, which aims to solve the problem that existing treatment methods are difficult to realize synchronous and coordinated improvement on key pathological phenotypes such as estrous cycle disorder, insulin resistance, and hyperandrogenemia, and the 5-methylcytidine involved is a pyrimidine nucleoside natural product, which is high in safety, low in toxic and side effects, and has unique curative effect in treatment of polycystic ovary syndrome.
Need to check novelty before this filing date? Find Prior Art